| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Total revenues and other income | 115,461 | |||
| Cost of captisol | 3,801 | |||
| Amortization of intangibles | 8,097 | |||
| Research and development | 21,019 | |||
| General and administrative | 28,446 | |||
| Financial royalty assets impairment | 0 | |||
| Fair value adjustments to partner program derivatives | 833 | |||
| Total operating costs and expenses | 60,530 | |||
| Operating income (loss) | 54,931 | |||
| Gain (loss) from short-term investments | 7,798 | |||
| Gain (loss) from change in fair value of equity-method investments and other investments | 75,887 | |||
| Interest income | 3,874 | |||
| Interest expense | 910 | |||
| Other non-operating expense, net | -443 | |||
| Total non-operating income (expenses), net | 86,206 | |||
| Income (loss) before income taxes | 141,137 | |||
| Income tax expense | 23,864 | |||
| Net income (loss) | 117,273 | |||
| Basic net income (loss) per share (in usd per share) | 5.99 | |||
| Diluted net income (loss) per share (in usd per share) | 5.68 | |||
| Shares used in basic per share calculation (in shares) | 19,578,000 | |||
| Shares used in diluted per share calculation (in shares) | 20,629,000 | |||
LIGAND PHARMACEUTICALS INC (LGNZZ)
LIGAND PHARMACEUTICALS INC (LGNZZ)